WallStreetZenWallStreetZen

NASDAQ: PROK
Prokidney Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PROK

Based on 1 analyst offering 12 month price targets for Prokidney Corp

Min Forecast
$12.00+555.74%
Avg Forecast
$12.00+555.74%
Max Forecast
$12.00+555.74%

Should I buy or sell PROK stock?

Based on 1 analyst offering ratings for Prokidney Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PROK's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PROK as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their PROK stock forecasts and price targets.

PROK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-18

1 of 1

Forecast return on equity

Is PROK forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is PROK forecast to generate an efficient return on assets?

Company
-36.3%
Industry
27.62%
PROK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PROK earnings per share forecast

What is PROK's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.59
Avg 2 year Forecast
-$0.69
Avg 3 year Forecast
-$0.45

PROK revenue forecast

What is PROK's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$501.8k-43.55%
Avg 2 year Forecast
$393.3k-55.76%
Avg 3 year Forecast
$59.3M+6,571.88%
PROK's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PROK revenue growth forecast

How is PROK forecast to perform vs Biotechnology companies and vs the US market?

Company
279.19%
Industry
34.07%
Market
14.06%
PROK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PROK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PROK vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PROK$1.83$12.00+555.74%Buy
MDXG$3.67$7.75+111.17%Strong Buy
TECX$30.02$72.00+139.84%Strong Buy
AGMB$10.98$32.00+191.44%Strong Buy
XOMA$41.89$44.50+6.23%Buy
View Top Biotech Stocks

Prokidney Stock Forecast FAQ

Is Prokidney Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PROK) stock is to Buy PROK stock.

Out of 1 analyst, 0 (0%) are recommending PROK as a Strong Buy, 1 (100%) are recommending PROK as a Buy, 0 (0%) are recommending PROK as a Hold, 0 (0%) are recommending PROK as a Sell, and 0 (0%) are recommending PROK as a Strong Sell.

If you're new to stock investing, here's how to buy Prokidney stock.

What is PROK's earnings growth forecast for 2026-2028?

(NASDAQ: PROK) Prokidney's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.

Prokidney's earnings in 2026 is -$72,289,000.On average, 9 Wall Street analysts forecast PROK's earnings for 2026 to be -$177,641,266, with the lowest PROK earnings forecast at -$192,411,982, and the highest PROK earnings forecast at -$155,409,678. On average, 9 Wall Street analysts forecast PROK's earnings for 2027 to be -$209,387,733, with the lowest PROK earnings forecast at -$375,943,411, and the highest PROK earnings forecast at -$126,865,043.

In 2028, PROK is forecast to generate -$136,168,479 in earnings, with the lowest earnings forecast at -$168,730,507 and the highest earnings forecast at -$114,178,539.

What is PROK's revenue growth forecast for 2026-2028?

(NASDAQ: PROK) Prokidney's forecast annual revenue growth rate of 279.19% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Prokidney's revenue in 2026 is $889,000.On average, 9 Wall Street analysts forecast PROK's revenue for 2026 to be $151,585,603, with the lowest PROK revenue forecast at $0, and the highest PROK revenue forecast at $286,714,997. On average, 9 Wall Street analysts forecast PROK's revenue for 2027 to be $118,794,312, with the lowest PROK revenue forecast at $0, and the highest PROK revenue forecast at $286,714,997.

In 2028, PROK is forecast to generate $17,916,062,597 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $66,006,069,474.

What is PROK's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: PROK) forecast ROA is -36.3%, which is lower than the forecast US Biotechnology industry average of 27.62%.

What is PROK's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PROK price target, the average PROK price target is $12.00, with the highest PROK stock price forecast at $12.00 and the lowest PROK stock price forecast at $12.00.

The Wall Street analyst predicted that Prokidney's share price could reach $12.00 by May 18, 2027. The average Prokidney stock price prediction forecasts a potential upside of 555.74% from the current PROK share price of $1.83.

What is PROK's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: PROK) Prokidney's current Earnings Per Share (EPS) is -$0.53. On average, analysts forecast that PROK's EPS will be -$0.59 for 2026, with the lowest EPS forecast at -$0.64, and the highest EPS forecast at -$0.51. On average, analysts forecast that PROK's EPS will be -$0.69 for 2027, with the lowest EPS forecast at -$1.24, and the highest EPS forecast at -$0.42. In 2028, PROK's EPS is forecast to hit -$0.45 (min: -$0.56, max: -$0.38).

What is PROK's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: PROK) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.